Literature DB >> 27089897

Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Lian-Ming Wu1, Zi-Zhou Zhao1, Xiao-Xi Chen1, Qing Lu1, Shi-Teng Suo1, Qiang Liu2, Jiani Hu3, E Mark Haccke3, Jian-Rong Xu1.   

Abstract

OBJECTIVE: To evaluate the diagnostic value of T2(*) mapping compared with apparent diffusion coefficient (ADC) mapping in the characterization of low-grade (Gleason score, ≤6) vs intermediate-grade and high-grade (Gleason score ≥7) prostate cancer (PCa).
METHODS: 62 patients who underwent MRI before prostatectomy were evaluated. Two readers independently scored the probabilities of tumours in 12 regions of the prostate on T2(*) and ADC images. The data were divided into two groups, i.e. low- vs intermediate- and high-grade PCa, and correlated with the histopathological results. The diagnostic performance parameters, areas under the receiver-operating characteristic curves and interreader agreements were calculated.
RESULTS: For Reader 2, ADC mapping exhibited a greater accuracy for intermediate-grade PCas than for high-grade PCas (0.77 vs 0.83, p < 0.05). For both readers, T2(*) mapping exhibited a greater accuracy for intermediate-grade PCas than for high-grade PCas (Reader 1, 0.86 vs 0.81; Reader 2, 0.83 vs 0.78; p < 0.05). The areas under the curve of T2(*) mappings were greater than those of the ADC mappings for the intermediate- and high-grade PCas (Reader 1, 0.83 vs 0.78; Reader 2, 0.80 vs 0.75; p < 0.05) but not for the low-grade PCas (Reader 1, 0.86 vs 0.84; Reader 2, 0.83 vs 0.82; p > 0.05). The weighted κ value of T2(*) mapping was 0.59.
CONCLUSION: T2(*) mapping improves the accuracy of the characterization of intermediate- and high-grade PCas but not low-grade PCas compared with ADC mapping. ADVANCES IN KNOWLEDGE: T2(*) mapping exhibited greater diagnostic accuracy than ADC mapping in the characterization of intermediate- and high-grade PCas. T2(*) mapping exhibited limited value in the characterization of low-grade PCa.

Entities:  

Mesh:

Year:  2016        PMID: 27089897      PMCID: PMC5257316          DOI: 10.1259/bjr.20151076

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  30 in total

1.  International variation in prostate cancer incidence and mortality rates.

Authors:  Melissa M Center; Ahmedin Jemal; Joannie Lortet-Tieulent; Elizabeth Ward; Jacques Ferlay; Otis Brawley; Freddie Bray
Journal:  Eur Urol       Date:  2012-03-08       Impact factor: 20.096

2.  Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation.

Authors:  Kazuhiro Katahira; Taro Takahara; Thomas C Kwee; Seitaro Oda; Yasuko Suzuki; Shoji Morishita; Kosuke Kitani; Yasuyuki Hamada; Mitsuhiko Kitaoka; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2010-07-18       Impact factor: 5.315

3.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Authors:  Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki Tsukuma
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

4.  T2 star relaxation times for assessment of articular cartilage at 3 T: a feasibility study.

Authors:  Tallal Charles Mamisch; Timothy Hughes; Timothy J Mosher; Christoph Mueller; Siegfried Trattnig; Chris Boesch; Goetz Hannes Welsch
Journal:  Skeletal Radiol       Date:  2011-04-19       Impact factor: 2.199

5.  Dissected sentinel lymph nodes of breast cancer patients: characterization with high-spatial-resolution 7-T MR imaging.

Authors:  Mies A Korteweg; Jaco J M Zwanenburg; Johannes M Hoogduin; Maurice A A J van den Bosch; Paul J van Diest; Richard van Hillegersberg; Marinus J C Eijkemans; Willem P T M Mali; Peter R Luijten; Wouter B Veldhuis
Journal:  Radiology       Date:  2011-06-14       Impact factor: 11.105

6.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Authors:  Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2010-12-21       Impact factor: 11.105

7.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.

Authors:  Courtney A Woodfield; Glenn A Tung; David J Grand; John A Pezzullo; Jason T Machan; Joseph F Renzulli
Journal:  AJR Am J Roentgenol       Date:  2010-04       Impact factor: 3.959

8.  Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Authors:  Thiele Kobus; Pieter C Vos; Thomas Hambrock; Maarten De Rooij; Christina A Hulsbergen-Van de Kaa; Jelle O Barentsz; Arend Heerschap; Tom W J Scheenen
Journal:  Radiology       Date:  2012-07-27       Impact factor: 11.105

9.  Feasibility and preliminary experience of quantitative T2* mapping at 3.0 T for detection and assessment of aggressiveness of prostate cancer.

Authors:  Lian-Ming Wu; Xiao-Xi Chen; Han-Qing Xuan; Qiang Liu; Si-Teng Suo; Jiani Hu; Jian-Rong Xu
Journal:  Acad Radiol       Date:  2014-08       Impact factor: 3.173

10.  Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study.

Authors:  Hyun Kyung Lim; Jeong Kon Kim; Kyung Ah Kim; Kyoung-Sik Cho
Journal:  Radiology       Date:  2008-11-18       Impact factor: 11.105

View more
  1 in total

1.  High spectral and spatial resolution MRI of prostate cancer: a pilot study.

Authors:  Milica Medved; Aritrick Chatterjee; Ajit Devaraj; Carla Harmath; Grace Lee; Ambereen Yousuf; Tatjana Antic; Aytekin Oto; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2021-05-08       Impact factor: 4.668

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.